Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
Version of Record online: 5 FEB 2014
© 2013 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 276, Issue 3, pages 260–268, September 2014
How to Cite
(University of Oxford, Oxford, UK; Leibniz-Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany; University of Oxford, Oxford, UK; Karolinska Institutet, Stockholm, Sweden) Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med 2014; 276: 260–268., , , , , , , , ,
- Issue online: 12 AUG 2014
- Version of Record online: 5 FEB 2014
- Accepted manuscript online: 23 DEC 2013 10:25AM EST
- British Heart Foundation (BHF). Grant Number: LSHM-CT-2007-037273
- Wellcome Trust
- UK Medical Research Council
- Swedish Heart–Lung Foundation
- Swedish Medical Research Council
- Knut and Alice Wallenberg Foundation
- Karolinska Institutet
Figure S1. Example of an immunoblot from the present study that was used to estimate the number of KIV repeats.
Figure S2. Association between geometric mean Lp(a) levels and KIV repeats in CHD cases and controls.
Table S1. Distribution of (a) Lp(a) levels and (b) KIV repeats (smallest isoform) within fifths (defined in controls).
Table S2. Classification by fifths of KIV repeats (smallest isoform) and Lp(a) levels shown as the proportion of (a) all individuals (b) CHD cases and controls separately.
Table S3. Characteristics by fifths of Lp(a) levels amongst controls.
Table S4. Characteristics by fifths of KIV (smallest isoform) repeats amongst controls.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.